Transatlantic Capital Inc. Signs Land Deal for 250 Acres; To Grow Cannabis and Psilocybin Mushrooms in Jamaica

Washington, D.C.--(Newsfile Corp. - October 23, 2020) - Transatlantic Inc. (OTC Pink: TACI) ("TACI") cuts deal for 250 acres in Clarendon, Jamaica.

This 250 acre parcel will allow the Company to create and build the largest cannabis and "magic mushroom" operation in the Caribbean. This facility could produce upwards of 100k pounds annually for export to licensed countries throughout the world.

"We are truly now, beginning to dig in," stated Julius Jenge, Chief Executive Officer of TACI, Inc. "Our commitment to research, production and distribution of psilocybin mushrooms and cannabis is now a reality, effective today, after acquiring the Clarendon Jamaica property. We now have a very solid plan in place, and we anticipate great things coming to fruition."

TRANSATLANTIC CAPITAL INC. FORWARD-LOOKING STATEMENTS

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts, including, without limitation, statements regarding the investment offerings and the terms thereof, are forward-looking statements. When used in this press release, words such as we "expect", "intend", "plan", "estimate", "anticipate", "believe", "should", or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information:

Julius Jenge, Chief Executive Officer
Phone: 1-804-573-7415
Email: juliusjenge@gmail.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66732